Jack Shuang Hou: CorTec Wins FDA TAP Entry for Brain Interchange
Jack Shuang Hou, Scientific Director at Jtests and CorDx, shared on LinkedIn:
”CorTec Wins FDA TAP Entry for Brain Interchange – Frank Desiere Highlights Third Stroke Rehab Implant as BCI Program Gains Regulatory Momentum
A meaningful neurotech milestone: CorTec has now secured both FDA Breakthrough Device Designation and acceptance into the FDA Total Product Life Cycle Advisory Program (TAP) for Brain Interchange in stroke motor rehabilitation, while advancing its NIH-funded clinical study with a third patient implanted at Harborview Medical Center.
Key leaders
- Frank Desiere – PhD MBA — Chief Executive Officer, CorTec
- Jeff Ojemann, MD — Vice Chair and Professor of Neurological Surgery, University of Washington – School of Medicine
- Martin Schuettler — Chief Technology Officer and Co-Founder, CorTec
- Mara Assis – Head of Regulatory Affairs and Quality Management, CorTec
FDA validation goes beyond breakthrough status
- Brain Interchange accepted into FDA TAP, a limited program for priority breakthrough technologies
- TAP adds structured FDA support on study design, regulatory strategy, and early payer engagement including CMS
- This follows CorTec’s recent Breakthrough Device Designation for stroke rehabilitation.
Strategic impact:
This is not just a regulatory badge – it strengthens the path from clinical evidence – approval – reimbursement.
Clinical execution is advancing in parallel
- Third patient implanted at Harborview Medical Center in Seattle
- Trial is NIH-funded, FDA-authorized, and conducted by researchers from University of Washington and UCLA
- First participant has now shown nine months of stable wireless sensing and cortical stimulation performance.
Signal:
CorTec is building both regulatory momentum and real human durability data at the same time.
A European neurotech platform gaining global relevance
- Brain Interchange is a fully implantable, wireless, bidirectional closed-loop BCI
- CorTec says it is the only European company with such a platform in FDA-authorized U.S. clinical evaluation
- The platform is also being explored in epilepsy, depression, and communication restoration.
My takeaway
This is a strong example of how next-generation neurotech wins:
- differentiated platform
- durable implant performance
- smart regulatory sequencing
- early reimbursement thinking
Bottom line
CorTec is moving Brain Interchange from promising BCI concept toward a real therapeutic platform for stroke recovery, and FDA TAP entry materially increases the credibility of that path.”
Stay updated with Hemostasis Today.
-
Jun 20, 2026, 22:23Bringing Conversations About Stroke and Men’s Health to the Melbourne Storm Community – Stroke Foundation
-
Jun 20, 2026, 21:03Johannes Grillari: Post-Stroke Senescence May Be More Adaptive Than Previously Thought
-
Jun 20, 2026, 19:51Sushmita Sen: How are We Doing in Global Clinical Trials and Precision Hematology?
-
Jun 20, 2026, 19:46Rainer Kaiser: How Neutrophils Stiffen Thrombi in Acute Ischemic Stroke
-
Jun 20, 2026, 19:38Muhammad Amjad Sohail: Stroke – Recognize the Signs, Save a Life
-
Jun 20, 2026, 19:36Osman Eladani: How Do We Optimize Bleeding Risk Management in Elective Surgery?
-
Jun 20, 2026, 19:26Abdul Mannan: Pregnancy Changes Almost Every Coagulation Test
-
Jun 20, 2026, 19:24Rubi Stephani Hellwege: Why Two Patients With the Same Cardiac Output Can Be Completely Different
-
Jun 20, 2026, 19:20Alexander Cohen: How Long Should You Treat VTE?